Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 08, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 153,679 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on December 6, 2005, and the Company was advised of it on December 7, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Key Facts for Investor Verification
- 153,679 Ordinary Shares were transferred from the GSK Trust to employee plan participants on December 6, 2005.
- The transaction was notified under Disclosure Rule 3.1.4R (1) (b).
- Three directors have an interest in the GSK Trust shares as potential beneficiaries alongside other employees.
- No financial performance metrics are included in this specific filing.